If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Company Update

5 Jul 2013 07:00

RNS Number : 6665I
Ark Therapeutics Group PLC
05 July 2013
 



Ark Therapeutics Group plc

 

Company Update

 

London, UK, 5 July 2013 - Ark Therapeutics Group plc (LSE: AKT) ("Ark") has been notified by Crawford Healthcare Ltd ("Crawford") that it is of the view that certain sales of its products (KerraMax Care) do not constitute relevant sales for the purposes of the earn-out consideration due to Ark (subject to certain revenue targets) under the sale agreement dated 7 February 2011 pursuant to which Ark's woundcare business was sold to Crawford Woundcare Limited. As such, in Crawford's view it is unlikely that the revenue targets will be met in respect of calendar year 2013. Ark strongly disagrees with the position Crawford is attempting to assert and, having taken legal advice, is confident that the product sales in question should be included in the relevant revenue targets which may or may not trigger earn-out consideration. Whilst any payment to Ark of deferred consideration remains subject to the agreed revenue targets being met in calendar year 2013, and as such no guarantee can be given as to the likelihood of those targets being met, Ark is confident that on the basis of advice its position is sound and it will take all steps available to it to protect its contractual rights.

 

Non-Executive Director, David Venables, comments:

 

"We were initially contacted by Crawford Healthcare to discuss their position in April and since then the Company has taken independent legal advice on the detail of the contract. Discussions continue, and we hope to resolve the matter amicably with Crawford Healthcare."

 

A further update will be provided in due course.

 

For further information please contact:

 

Ark Therapeutics Group plc

Tel: +44 (0)207 002 1005 

 

Iain G Ross, Non-Executive Chairman

 

David Venables, Non-Executive Director

 

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFETDDISIIV
Date   Source Headline
14th Apr 20102:09 pmRNSRule 8.3- Ark Therapeutics Group PLC
14th Apr 201011:41 amRNSEPT Disclosure-Amendment
13th Apr 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
13th Apr 201011:34 amRNSEPT Disclosure
13th Apr 201011:31 amRNSRule 8.3- ARK THERAPEUTICS
13th Apr 201011:29 amRNSEPT Disclosure
12th Apr 201011:22 amRNSEPT Disclosure
12th Apr 201010:19 amRNSEPT Disclosure
12th Apr 20107:00 amRNSResearch Update
9th Apr 201011:35 amRNSEPT Disclosure
9th Apr 201011:33 amRNSEPT Disclosure- Amendment
9th Apr 20109:28 amRNSEPT Disclosure
8th Apr 20102:43 pmRNSEPT Disclosure-Amendment
8th Apr 201012:27 pmRNSEPT Disclosure
8th Apr 201010:43 amRNSRule 8.3- ARK THERAPEUTICS
8th Apr 20108:33 amRNSEPT Disclosure
7th Apr 20104:08 pmRNSAnnual Information Update
7th Apr 201010:59 amRNSRule 8.3- ARK THERAPEUTICS
1st Apr 201011:03 amRNSArk Therapeutics Group plc
1st Apr 201011:00 amRNSEPT Disclosure
1st Apr 201010:37 amRNSEPT Disclosure
31st Mar 20103:42 pmRNSTotal Voting Rights
31st Mar 20102:00 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
31st Mar 201010:37 amRNSEPT Disclosure
30th Mar 201012:48 pmRNSEPT Disclosure
30th Mar 201012:42 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201010:53 amRNSEPT Disclosure
24th Mar 201011:52 amRNSEPT Disclosure
24th Mar 201011:15 amRNSEPT Disclosure
24th Mar 201010:25 amBUSRule 8.3 - Ark Therapeutics Group plc
22nd Mar 20101:48 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:42 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:24 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
22nd Mar 201011:45 amRNSEPT Disclosure
22nd Mar 201010:18 amRNSEPT Disclosure
19th Mar 20104:58 pmRNSRule 8.3- (Ark Therapeutics Group Plc)
19th Mar 20102:56 pmRNSRule 8.3- Ark Therapeutics Group plc
19th Mar 20101:30 pmBUSRule 8.3 - Ark Therapeutics Group plc
19th Mar 201011:45 amRNSEPT Disclosure
19th Mar 201010:30 amRNSEPT Disclosure
18th Mar 201012:14 pmRNSEPT Disclosure
17th Mar 201010:38 amRNSEPT Disclosure
16th Mar 20103:55 pmRNSHolding(s) in Company
16th Mar 201011:12 amRNSEPT Disclosure
15th Mar 201011:30 amRNSEPT Disclosure
15th Mar 201010:34 amRNSEPT Disclosure
11th Mar 201011:49 amRNSEPT Disclosure
10th Mar 20104:40 pmRNSSecond Price Monitoring Extn
10th Mar 20104:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.